Warning letter
LifeSouth Community Blood Centers, Inc.: warning letter of Sep 26, 2003
FDA warning letter UCM147742 · New Orleans District Office
Key facts
| Reference number | UCM147742 |
|---|---|
| Company | LifeSouth Community Blood Centers, Inc. |
| Subject | GMP for Finished Pharmaceuticals/GMP for Blood & Blood Components |
| Issue date | Sep 26, 2003 |
| Posted date | Sep 26, 2003 |
| Issuing office | New Orleans District Office |
| Product type | Biologics |
| CFR sections cited | 606.171, 211.192, 211.22(a), 211.100(a), 211.100(b), 606.160, 606.100(b)(17), 606.100(c), 606.100(b) |
| Country | 3 |
| Inspection city | Birmingham |
| Inspection ZIP | 35209-6321 |
| Inspection start date | Jun 18, 2003 |
| Letter on fda.gov | web.archive.org |
At a glance
- 1–9 CFR sections cited
- OAI Linked inspection classification
- Yes Form FDA 483 issued
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA warning letters
FDA warning letters notify a firm of significant regulatory violations found during an inspection or review and request prompt corrective action.
Source: U.S. Food and Drug Administration (FDA), Warning Letters · Source date: